UNSPSC 85812114: Introduction of liquid brachytherapy radioisotope into eye, percutaneous approach

This classification denotes the group of activities that yields a administrative intervention or procedure to introduction of liquid brachytherapy radioisotope into eye, percutaneous approach. This administrative intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 3E0C304

UNSPSC 85812114 Introduction of liquid brachytherapy radioisotope into eye, percutaneous approach is a Commodity code that bears little relevant connection to state and local procurement activity in the recent opportunities record. The code describes an invasive clinical procedure—liquid radioisotope injection into the eye—yet the recent opportunities tagged under this code are unrelated to brachytherapy, radiation oncology, or ophthalmic radiological procedures. The Inland Empire Health Plan solicitation seeks virtual urgent care services delivered by board-certified physicians via telehealth, a fundamentally different service line from radiation therapy. The DeKalb County and Nevada Health Authority opportunities address PACE operations, general medical services, and rural value-based care facilitation—none involving brachytherapy. San Mateo County's cancer registry and retinal screening device solicitations relate to oncology support and diagnostic imaging, not radioisotope injection. The code shows no recent activity aligned with its technical definition and nominal scope.

State and local procurement activity under this code is not demonstrable in the available recent opportunities. The mismatch between the code's narrow clinical focus and the broad spectrum of health services actually being solicited suggests either miscoding by issuing bodies or that the code genuinely does not reflect active state and local spending patterns. Pursue this code only if your firm offers ophthalmic brachytherapy services and can independently verify that state and local health systems—primarily state departments of health, county hospital authorities, academic medical centers, or integrated delivery systems—are actually purchasing these services. The evidence base does not support current market activity.